Approval · Notice of Compliance 13813 · 2012
ZEMPLAR: Notice of Compliance 13813
Issued November 2, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13813
- Date
- November 2, 2012
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- manufacturer name change
- Therapeutic class
- Vitamin D analogue
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZEMPLAR | 02266202 | Cancelled Post Market |
| ZEMPLAR | 02302497 | — |
| ZEMPLAR | 02302500 | — |
| ZEMPLAR | 02302519 | — |
Medicinal ingredients
- PARICALCITOL 5 MCG per ML
- PARICALCITOL 1 MCG per CAP
- PARICALCITOL 2 MCG per CAP
- PARICALCITOL 4 MCG per CAP